Joshua Richter, MD, FACP

Financial relationships

  • Attribution:
    Self
    Nature of financial relationship:
    Other
    Ineligible company:
    Janssen
    Topic:
    Myeloma
    Date added:
    01/31/2025
    Date updated:
    01/31/2025
  • Attribution:
    Self
    Nature of financial relationship:
    Other
    Ineligible company:
    BMS
    Topic:
    Myeloma
    Date added:
    01/31/2025
    Date updated:
    01/31/2025
  • Attribution:
    Self
    Nature of financial relationship:
    Other
    Ineligible company:
    Pfizer
    Topic:
    Myeloma
    Date added:
    01/31/2025
    Date updated:
    01/31/2025
  • Attribution:
    Self
    Nature of financial relationship:
    Other
    Ineligible company:
    Karyopharm
    Topic:
    Myeloma
    Date added:
    01/31/2025
    Date updated:
    01/31/2025
  • Attribution:
    Self
    Nature of financial relationship:
    Other
    Ineligible company:
    Sanofi
    Topic:
    Myeloma
    Date added:
    01/31/2025
    Date updated:
    01/31/2025
  • Attribution:
    Self
    Nature of financial relationship:
    Other
    Ineligible company:
    Adaptive Biotechnologies
    Topic:
    MRD
    Date added:
    01/31/2025
    Date updated:
    01/31/2025
  • Attribution:
    Self
    Nature of financial relationship:
    Other
    Ineligible company:
    Takeda
    Topic:
    Myeloma
    Date added:
    01/31/2025
    Date updated:
    01/31/2025
  • Attribution:
    Self
    Nature of financial relationship:
    Other
    Ineligible company:
    Genentech
    Topic:
    Myeloma
    Date added:
    01/31/2025
    Date updated:
    01/31/2025
  • Attribution:
    Self
    Nature of financial relationship:
    Other
    Ineligible company:
    Abbvie
    Topic:
    Myeloma
    Date added:
    01/31/2025
    Date updated:
    01/31/2025
  • Attribution:
    Self
    Nature of financial relationship:
    Other
    Ineligible company:
    Regeneron
    Topic:
    Myeloma
    Date added:
    01/31/2025
    Date updated:
    01/31/2025

Pages

Return to 14th Annual Updates in the Treatment and Management of Hematologic Malignancies Highlights from San Diego